Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,488.20GBp
11 Dec 2018
Change (% chg)

18.60 (+1.27%)
Prev Close
1,469.60
Open
1,478.00
Day's High
1,495.00
Day's Low
1,476.40
Volume
7,788,819
Avg. Vol
8,172,340
52-wk High
1,648.80
52-wk Low
1,235.20

Latest Key Developments (Source: Significant Developments)

Crown Laboratories Acquires Select Consumer Healthcare Brands From Glaxosmithkline
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Crown Laboratories ::CROWN LABORATORIES ACQUIRES SELECT CONSUMER HEALTHCARE BRANDS FROM GLAXOSMITHKLINE.FINANCIAL TERMS OF TRANSACTION WERE NOT DISCLOSED.HAS ACQUIRED NORTH AMERICAN DISTRIBUTION RIGHTS OF 5 OTC CONSUMER BRANDS FROM GLAXOSMITHKLINE.SAYS HAYFIN CAPITAL MANAGEMENT, LLP PROVIDED DEBT FINANCING IN CONNECTION WITH TRANSACTION.  Full Article

GSK Says Considering Potential Deal Including Merger Of Its Consumer Healthcare Unit
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - GlaxoSmithKline Plc ::UPDATE ON REVIEW OF HORLICKS.GSK CONFIRMS THAT CONSIDERATION IS BEING GIVEN TO A POTENTIAL TRANSACTION THAT INCLUDES A MERGER OF GSKCH.MAJORITY OF HORLICKS AND OTHER GSK NUTRITION PRODUCTS SALES ARE GENERATED IN INDIA BY GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED.  Full Article

Novitium Pharma Launches Ranitidine Capsules
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Novitium Pharma LLC::NOVITIUM PHARMA LAUNCHES RANITIDINE CAPSULES.NOVITIUM PHARMA LLC - RECEIVED FDA APPROVAL ON ITS ABBREVIATED NEW DRUG APPLICATION FOR RANITIDINE CAPSULES 150 MG AND 300 MG .NOVITIUM PHARMA LLC - RANITIDINE IS A THERAPEUTIC EQUIVALENT TO REFERENCE LISTED DRUG ZANTAC OF GLAXOSMITHKLINE PLC .  Full Article

GSK, Kyowa Hakko Kirin Sign Commercialisation Deal In Japan For Daprodustat
Thursday, 22 Nov 2018 

Nov 22 (Reuters) - GlaxoSmithKline Plc ::GSK AND KYOWA HAKKO KIRIN SIGN STRATEGIC COMMERCIALISATION DEAL IN JAPAN FOR DAPRODUSTAT.  Full Article

GSK Submits U.S. Regulatory Filing To Expand Nucala Use
Monday, 19 Nov 2018 

Nov 19 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - GSK SUBMITS US REGULATORY FILING TO EXPAND USE OF NUCALA IN CHILDREN WITH SEVERE EOSINOPHILIC ASTHMA.  Full Article

Theravance Biopharma Highlights Expanded COPD Indication For Trelegy Ellipta In Europe
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA HIGHLIGHTS EXPANDED COPD INDICATION FOR TRELEGY ELLIPTA IN EUROPE.THERAVANCE BIOPHARMA INC - EUROPEAN COMMISSION AUTHORIZED AN EXPANDED LABEL FOR ONCE-DAILY TRELEGY ELLIPTA.  Full Article

GSK Says European Commission Authorised Expanded Label For Once-Daily Trelegy Ellipta
Friday, 9 Nov 2018 

Nov 9 (Reuters) - GlaxoSmithKline PLC ::ONCE-DAILY TRELEGY ELLIPTA GAINS EXPANDED COPD INDICATION IN EUROPE.CO, INNOVIVA ANNOUNCED THAT EUROPEAN COMMISSION AUTHORISED EXPANDED LABEL FOR ONCE-DAILY TRELEGY ELLIPTA.  Full Article

Hikma Announces Agreement With Vectura
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Hikma Pharmaceuticals Plc ::HIKMA ANNOUNCES AGREEMENT WITH VECTURA.UPON SIGNING, HIKMA WILL MAKE AN UPFRONT PAYMENT OF $15 MILLION TO VECTURA.VECTURA WILL BE RESPONSIBLE FOR, AND FUND, INITIAL DEVICE AND FORMULATION DEVELOPMENT.DEAL FOR GLOBAL DEVELOPMENT AND COMMERCIALISATION OF GENERIC VERSIONS OF GSK'S ELLIPTA PORTFOLIO.UPON TRANSFER OF 1ST PRODUCT TO CO'S MANUFACTURING FACILITY, WILL MAKE $5 MILLION MILESTONE PAYMENT TO VECTURA.THEREAFTER, HIKMA WILL MAKE MILESTONE PAYMENTS OF UP TO $75 MILLION AT VARIOUS STAGES OF DEVELOPMENT.VECTURA WILL CONTRIBUTE UP TO $70 MILLION TOWARDS HIKMA'S DEVELOPMENT ACTIVITIES FOR PORTFOLIO.HIKMA PHARMACEUTICALS - VECTURA'S CONTRIBUTION TO BE MADE THROUGH REDUCED PROFIT SHARE MECHANISM FOLLOWING COMMERCIAL LAUNCH OF FIRST PRODUCT.  Full Article

GSK's Viiv Says Positive Phase III Results With Fostemsavir
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - GlaxoSmithKline PLC ::VIIV POSITIVE PHIII RESULTS WITH FOSTEMSAVIR.PHASE III RESULTS SHOW 54% OF PATIENTS IN RANDOMISED COHORT ACHIEVED VIROLOGIC SUPPRESSION AT 48 WEEKS OF TREATMENT.PATIENTS IN RANDOMISED COHORT SHOWED IMMUNOLOGIC IMPROVEMENT THROUGH WEEK 48 AS DEMONSTRATED BY AN INCREASE IN CD4+ T-CELL COUNTS.EXPECT TO SEEK REGULATORY APPROVAL FOR FOSTEMSAVIR IN 2019.  Full Article

GSK Sees Encouraging Long-Term Results For HIV Long-Acting Injectable Study
Monday, 29 Oct 2018 

Oct 29 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - VIIV - THREE-YEAR DATA FOR LONG-ACTING INJECTABLE.GLAXOSMITHKLINE PLC - VIIV HEALTHCARE PRESENTS THREE-YEAR DATA FOR INVESTIGATIONAL LONG-ACTING INJECTABLE, TWO-DRUG HIV REGIMEN.GSK - AT 160 WEEKS, LONG-ACTING REGIMEN, ADMINISTERED EITHER EVERY EIGHT WEEKS OR EVERY FOUR WEEKS, DEMONSTRATED HIGH RATES OF VIROLOGIC RESPONSE.GLAXOSMITHKLINE - MAJORITY OF PARTICIPANTS REPORTED AN INJECTION SITE REACTION THROUGH WEEK 160, OF WHICH 85% WERE MILD AND 14% WERE MODERATE..  Full Article

Photo

Shares stage tentative recovery as May seeks Brexit deal tweaks

MILAN UK shares sought to join a global equity recovery on Tuesday as the pound stabilised above 20-month lows, although banks and other domestically exposed stocks fell further as uncertainty grew over Britain's exit from the European Union.